Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer.
Sarhan D, Eisinger S, He F, Bergsland M, Pelicano C, Driescher C, Westberg K, Benitez II, Humoud R, Palano G, Li S, Carannante V, Muhr J, Önfelt B, Schlisio S, Ravetch JV, Heuchel R, Löhr MJ, Karlsson MCI. Sarhan D, et al. Among authors: ravetch jv. iScience. 2022 Oct 9;25(11):105317. doi: 10.1016/j.isci.2022.105317. eCollection 2022 Nov 18. iScience. 2022. PMID: 36310582 Free PMC article.
FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies.
Knorr D, Leidner R, Jensen S, Meng R, Jones A, Ballesteros-Merino C, Bell RB, Baez M, Sprott D, Bifulco C, Piening B, Dahan R, Fox BA, Ravetch J. Knorr D, et al. bioRxiv [Preprint]. 2023 Jan 20:2023.01.19.522856. doi: 10.1101/2023.01.19.522856. bioRxiv. 2023. Update in: Cancer Immunol Res. 2024 Mar 4;12(3):322-333. doi: 10.1158/2326-6066.CIR-23-0389 PMID: 36711504 Free PMC article. Updated. Preprint.
IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer.
Wong JL, Smith P, Angulo-Lozano J, Ranti D, Bochner BH, Sfakianos JP, Horowitz A, Ravetch JV, Knorr DA. Wong JL, et al. Among authors: ravetch jv. bioRxiv [Preprint]. 2023 Feb 1:2023.01.30.526266. doi: 10.1101/2023.01.30.526266. bioRxiv. 2023. Update in: Proc Natl Acad Sci U S A. 2023 Aug 29;120(35):e2306782120. doi: 10.1073/pnas.2306782120 PMID: 36778311 Free PMC article. Updated. Preprint.
Potent efficacy of an IgG-specific endoglycosidase against IgG-mediated pathologies.
Sastre DE, Bournazos S, Du J, Boder EJ, Edgar JE, Azzam T, Sultana N, Huliciak M, Flowers M, Yoza L, Xu T, Chernova TA, Ravetch JV, Sundberg EJ. Sastre DE, et al. Among authors: ravetch jv. Cell. 2024 Nov 27;187(24):6994-7007.e12. doi: 10.1016/j.cell.2024.09.038. Epub 2024 Oct 21. Cell. 2024. PMID: 39437779
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.
Knorr DA, Blanchard L, Leidner RS, Jensen SM, Meng R, Jones A, Ballesteros-Merino C, Bell RB, Baez M, Marino A, Sprott D, Bifulco CB, Piening B, Dahan R, Osorio JC, Fox BA, Ravetch JV. Knorr DA, et al. Among authors: ravetch jv. Cancer Immunol Res. 2024 Mar 4;12(3):322-333. doi: 10.1158/2326-6066.CIR-23-0389. Cancer Immunol Res. 2024. PMID: 38147316 Free PMC article.
269 results